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analysis was to develop two cost effectiveness models taking into account the 
new management of the treatment of AF and VTE in France. The clinical and cost 
benefits of VKA (with/without the use of a PAS) has been evaluated versus new 
oral anticoagulants (NOAC): dabigatran, rivaroxaban and apixaban. Methods: 
A Markov model was built for the treatment of AF and a decision tree for the 
treatment and prevention of VTE. In the VKA arms, both models integrate the pos-
sibility to adjust the percentage of time spent by patients within INR therapeutic 
range. In the VTE model, outcomes were expressed in cost per avoided event 
whereas in the AF model in cost per QALY. Results: In both models, apixaban is 
the strategy producing the least thromboembolic and hemorrhagic events whereas 
AVK strategies are the cheapest treatments (2 to 2.5 times less than NOAC treat-
ments). The use of the software for the treatment and prevention of VTE allows 
to save € 3,192 per avoided event and for the AF treatment € 7,557 per extra QALY 
gained and € 6,688 per avoided event. ConClusions: Based on French guide-
lines for economic evaluation, apixaban and VKA + PAS are efficient strategies 
in AF.
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objeCtives: As new therapies for chronic heart failure with reduced ejection 
fraction (HFrEF) emerge, health technology assessments (HTAs) will require cost-
effectiveness analyses to inform decision making. The objective was to develop 
a model framework for evaluating the cost-effectiveness of LCZ696, a novel oral 
therapy proposed for the treatment of HFrEF. Methods: A systematic literature 
review was performed. Searches were conducted in MEDLINE, EMBASE, EconLit, and 
Cochrane Library databases, with supplementary hand searching of conferences and 
HTA websites. Of 63 distinct analyses identified, 33 used decision-analytic models. 
Structures were most commonly described as Markov models (n= 27), but meth-
ods employed were heterogeneous. The health states most frequently employed 
were ‘alive’ and ‘dead’, with outcomes such as hospitalization or New York Heart 
Association (NYHA) class distribution most commonly considered within the ‘alive’ 
state. Results: A 2-state Markov model with ‘alive’ and ‘dead’ states was developed 
using three multivariate regression models to predict the risks of mortality, hospi-
talisation and the trajectory of health-related quality of life over time within the 
‘alive’ state. NYHA class was not used as a basis for health states, as the extrapola-
tion of clinical improvements beyond the observed data was considered clinically 
implausible. Parametric survival models, negative binomial models and multilevel 
models are used to predict mortality, hospitalisation, and HRQL, respectively, allow-
ing extrapolation to a lifetime time horizon. The model of HRQL attempts to cap-
ture the effects of baseline characteristics, hospitalisation, adverse events and time 
on EQ-5D. Clinical experts were consulted to validate the regression models and 
their respective predictions. ConClusions: The new framework employs similar 
methods to decision analytic models developed previously in heart failure, however 
models health-related quality of life as a function of time directly, thereby providing 
a parsimonious approach with improved clinical plausibility compared to other 
model structures in the literature.
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objeCtives: Venous thromboembolism (VTE) which comprises deep vein throm-
bosis (DVT) and pulmonary embolism (PE) is associated with a significant health-
care burden. Currently, the standard of care is parenteral low molecular weight 
heparin (enoxaparin) plus warfarin. Rivaroxaban is an oral anticoagulant that 
does not require dose adjustment or routine coagulation monitoring, bringing 
an important advantage for the treatment of VTE. The EINSTEIN clinical pro-
gram of rivaroxaban showed that, overall, hospitalized patients who received 
initial treatment with rivaroxaban for DVT and PE had a significantly shorter 
length of stay compared to patients who received enoxaparin/VKA. Therefore, 
the aim of this study was to compare the direct costs of treatment with rivar-
oxaban versus enoxaparin/warfarin. Methods: A cost-minimization analysis 
(CMA) was chosen once the EINSTEN program showed that rivaroxaban is non-
inferior to enoxaparin/VKA with regards to efficacy for treatment of VTE being 
possible to consider that there is no difference in outcomes. Perspective was 
from the Brazilian private healthcare system and time horizon was one year. 
Costs related to hospitalization, outpatient management and adverse events 
were obtained by micro-costing approach and resource use captured from lit-
erature and expert panel. Costs were expressed in 2015 prices and exchange rate 
used was $1.00USD= 3.00BRL. Results: Rivaroxaban use resulted less expen-
sive than enoxaparin+warfarin in the treatment of VTE. Estimated total cost of 
treatment for one patient with VTE is $2,079 with rivaroxaban and $2,716 with 
enoxaparin+warfarin. The greater difference in costs was for treatment of PE, which 
was $688.57 less for rivaroxaban. For DVT treatment, estimated savings for rivar-
oxaban was $561.46. Robustness of the model was tested in a deterministic univar-
iate sensitivity analysis in which all results remained cost saving. ConClusions: 
Rivaroxaban is a cost-saving alternative compared to the current practice for 
the treatment of VTE under the perspective of the Brazilian private healthcare 
system.
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objeCtives: In-situ tissue-engineering provides a promising method to cre-
ate living heart valves with the potential to grow, repair and last a lifetime. The 
objective of the present study is to develop a conceptual model (CM) that can be 
used to investigate the requirements for tissue-engineered heart valves (TEHV) to 
become cost-effective compared to current surgical and transcatheter heart valve 
substitutes (HVS). Methods: The development of the CM was based on recom-
mendations from the ISPOR-SMDM Modeling Good Research Practices Task Force-2. 
After scoping the decision problem, a draft CM was developed based on clinical 
guidelines and discussion within a small workgroup. This model was compared 
with existing models for cost-effectiveness of HVS, found by systematic literature 
search. It was further discussed with a Delphi panel of cardio-thoracic surgeons, 
cardiologists and a biomedical scientist (n= 10). Delphi panelists were first inter-
viewed individually to discuss the CM structure. Thereafter, they completed online 
surveys in order to reach consensus between panelists. Results: Health states 
included in the CM are ‘alive without complications’, cerebrovascular accident, 
myocardial infarction, vascular complication, bleeding, acute kidney injury, atrial 
fibrillation, pacemaker implantation, prosthetic valve dysfunction, prosthetic 
valve thrombosis, prosthetic valve endocarditis, ‘alive after complications’ and 
dead. Predictors of transition probabilities between the health states are included; 
age, gender, NYHA functional class, left ventricular function, renal impairment, 
and diabetes. Relevant outcome measures included health-related quality of 
life, event occurrence, event-free survival, mortality and costs. ConClusions: 
The CM provides the foundation of a microsimulation model that will be used 
to estimate the cost-effectiveness of TEHV compared with current HVS. The 
results will be used to inform stakeholders about the requirements for TEHV to 
become cost-effective. This information can help bio-tech companies to decide 
about further development of TEHV, focus on the most promising target groups, 
set realistic performance-price goals, and design and manage a reimbursement 
strategy.
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objeCtives: The World Health Organization guidelines recommend that an 
increase of potassium intake reduce blood pressure in adults. In addition, inter-
vention with vitamin B2 has been shown to lower blood pressure in patients with 
genotype, specifically in hypertensive patients with premature cardiovascular dis-
ease (CVD) homozygous for the 677C→ T polymorphism (TT genotype) in the gene 
encoding for the enzyme methylenetetrahydrofolate reductase. In the Chinese 
northern region, the prevalence of this TT genotype was estimated to be 35% of the 
population. Furthermore, 26% of adults are hypertensive and 20% adults will experi-
ence a CVD episode.This study aims to evaluate the impact of increased intake of 
potassium and vitamin B2 have on blood pressure, CVD events and quality-of-life 
among Chinese adults older than 45 years old. Furthermore this study assesses the 
costs and cost-effectiveness of achieving this impact via the consumption of a forti-
fied milk product. Methods: An analytical decision model was used to quantify 
and compare three strategies against the current intake of the at-risk-population: 1) 
Increased potassium intake level 2) Increased vitamin B2 intake level 3) Combined 
increased vitamin B2 and potassium intake levels. The effectiveness of these strate-
gies in incrementing vitamin B2 and potassium were determined by patient level 
data and the Framingham methodology. All costs and epidemiological data were 
collected from the literature. Results: All strategies led to statistically significant 
health outcomes due to the preventive effect of increased intake of potassium and 
vitamin B2 also resulting in a significant Quality Adjusted Life Years gain over the 
baseline. Each strategy is shown to be cost-effective or highly cost-effective with 
the largest effect being the combined increased intake of potassium and vitamin 
B2. ConClusions: The strategy of the combined increased intake of vitamin B2 
and potassium is highly cost-effective thereby preventing CVD events and saving 
costs to the health system.
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objeCtives: Vitamin K Antagonist (VKA) have traditionally been the main treat-
ment for thromboembolic event prevention in atrial fibrillation (AF) and for the 
treatment of venous and pulmonary thromboembolic events (VTE) and the pre-
vention of their relapses. A close patient monitoring with the determination of 
the INR (International Normalized Ratio) is needed during the AVK treatment, to 
avoid adverse thrombotic or hemorrhagic events. The improvement of the time 
spent in the therapeutic range (TTR), depending on INR results, has previously 
been studied in France with the use of a prescription assistance software (PAS). 
The use of this PAS improves the TTR from 58.46% to 71.79%. The objective of the 
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SoC and SoC alone gained 0.3155 QALYs and 0.2752 QALYs, respectively. Hence, 
ranolazine plus SoC resulted in an ICER of € 4,620 per QALY gained, well below the 
threshold of € 34,000 per QALY gained, that is twice the annual per capita income. 
The PSA showed that the likelihood of ranolazine plus SoC being cost-effective at 
the threshold of € 34,000 per QALY gained was 100%. ConClusions: The results 
suggest that ranolazine as add–on treatment may be a cost-effective alterna-
tive for the symptomatic treatment of patients with chronic stable angina in 
Greece.
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objeCtives: To evaluate the cost-effectiveness of apixaban vs. existing thera-
peutic alternatives (fondaparinux/VKA, LMWH/VKA, rivaroxaban, dabigatran) 
in the acute treatment and prevention of venous thromboembolism (VTE) from 
the French National healthcare insurance perspective. Methods: A cohort of 
simulated patients with VTE were placed on one of five therapeutic strategies for 
6-months and tracked over a course of 5-years in a Markov model. Modeled clinical 
events included recurrent VTE, major bleed, clinically-relevant non-major bleed, 
chronic thromboembolic pulmonary hypertension, post-thrombotic syndrome and 
death. Data on efficacy and safety were derived from a network meta-analysis. 
Medical costs of clinical events were extracted from a dedicated analysis of French 
health administrative databases and utility data were derived from literature. To 
assess the costs and benefits of extended treatment, treatment durations of 12 
and 18 months were examined in scenario analyses. Additionally, probabilistic 
sensitivity analyses that accounted for uncertainty in model parameters were 
conducted for each comparator. Results: Over treatment duration of 6 months 
at lifetime time horizon, apixaban was the dominant (less costly and more effec-
tive) alternative (6,573€ and 3.38 QALYs) compared to fondaparinux/VKA (6,621€ 
and 3.37 QALYs), LMWH/VKA (6,639€ and 3.37 QALYs), rivaroxaban (6,734€ and 3.38 
QALYs) and dabigatran (6,732€ and 3.37 QALYs). Probabilistic sensitivity analyses 
revealed apixaban was more likely to be cost-effective than all other strategies. 
Considering an extended treatment duration of 12 months, apixaban remained 
dominant versus rivaroxaban and dabigatran but cost-effective compared to fon-
daparinux/VKA (ICUR: 3,098€ /QALY) and LMWH/VKA (ICUR 2,381€ /QALY). Similar 
results were observed for treatment duration of 18 months with an increase of 
ICUR to 5,634€ /QALY and 5,083€ /QALY, respectively. ConClusions: Apixaban can 
offer substantial clinical and economic benefits over alternative therapies for 
acute and extended treatment of VTE.
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objeCtives: To conduct a systematic review on the pharmacoeconomic value of 
ranolazine vs standard-of-care (SOC) for the treatment of symptomatic chronic 
stable angina (CSA). Methods: Medline, Cochrane Library and Cost-Effectiveness 
Analysis Registry without time limits were searched. Articles in English were iden-
tified with the following keywords: cost, economic, ranolazine, ranexa, angina, 
coronary artery disease. The identified studies were independently reviewed by 
two investigators against pre-determined inclusion and exclusion criteria. The 
Quality of Health Economic Studies scale was used to assess the quality of the 
included studies. The data of selected studies were extracted onto a data extrac-
tion form and consequently were synthesized. Costing and effectiveness data for 
each comparator, incremental cost per quality-adjusted-life year (QALY) gained and 
results from sensitivity analyses were extracted. Results: Five studies containing 
evidence on effectiveness and cost of ranolazine were included in the review. Four 
of these studies assessed the cost–utility of ranolazine added to SOC compared to 
SOC alone, using decision tree or Markov models whereas one was a retrospective 
cost–comparative study. In all studies, patients were stratified according to their 
angina frequency symptoms. The analysis was conducted from a payer perspective 
in 4 studies and from the societal perspective in 1 study. The time horizon of analysis 
did not exceed the 1 year at any study. Ranolazine appeared to be cost-effective 
since it reduced the number of angina-related hospitalizations and improved qual-
ity of life with an Incremental Cost–Effectiveness Ratio (ICER) varying from € 4,000 
to € 15,000 per QALY gained. The ranolazine acquisition cost was the variable that 
mainly drove the ICER. ConClusions: The existing evidence showed that ranola-
zine is cost–effective for the second–line treatment of patients with symptomatic 
CSA, added to SOC. Further research is required to evaluate the cost – effectiveness 
of ranolazine in each angina frequency group.
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objeCtives: Cost-effectiveness analysis for secondary prevention with statins in 
Brazilian context are few and with efficacy data supported from primary RCT and 
utility values from foreign populations. Effectiveness from observational database 
and utility values from a similar population provides real world evidence. The aim of 
this study is to evaluate the cost-utility of secondary prevention with statins in fatal 
and non-fatal events based on real world data. Methods: A cohort markov model 
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objeCtives: This evaluation aimed to assess the cost-effectiveness of edoxaban 
60mg versus warfarin for the prevention of stroke and systemic embolic events 
among patients with non-valvular atrial fibrillation (NVAF) in the UK, from the 
perspective of the NHS. Methods: A Markov model was developed to simulate 
the course of disease in hypothetical cohorts of patients with NVAF and to assess 
the cost-effectiveness of edoxaban versus the current UK standard of care, warfa-
rin. The model used data from the ENGAGE study, and was based on patients with 
CHADS2 ≥ 2. Utility values were derived from systematic literature reviews. Costs 
were extracted from the literature and the NHS reference cost database; both were 
discounted at 3.5% per annum. Health outcomes were assessed in quality-adjusted 
life years (QALYs), and evaluated over a lifetime time horizon. Deterministic and 
probabilistic sensitivity analyses (PSA) were conducted to evaluate the effect of 
uncertainty in input parameters on the results. Results: In the base case analysis 
(CHADS2 ≥ 2), the incremental cost-effectiveness ratio (ICER) for edoxaban compared 
with warfarin was £12,881 per QALY gained. At a threshold of £20,000 per QALY, the 
net monetary benefit associated with edoxaban was £1,406. Edoxaban was also cost 
effective compared with warfarin in higher risk (CHADS2≥ 3) and higher anticoagu-
lant control (cTTR≥ 60%) subgroups (ICER £7,012 and £20,376 per QALY, respectively). 
Sensitivity analyses support these findings, and show that conclusions are robust to 
alternative assumptions about model inputs. Starting age, edoxaban cost, monitor-
ing costs and mortality due to non-ICH major bleeds are the drivers of the results. 
PSA indicates that 82% of simulations are in the north-east quadrant of the cost-
effectiveness plane for this comparison, and that the probability that edoxaban is 
cost-effective versus warfarin is more than 50%. ConClusions: Compared with 
warfarin, edoxaban represents a cost-effective alternative for stroke prevention in 
UK patients with NVAF.
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objeCtives: Randomized controlled trials have shown favorable effects of poly-
phenols and flavonoids found in chocolate on various cardiometabolic risk factors, 
including inflammatory markers, blood pressure, lipids, and insulin sensitivity. 
Epidemiologic studies also suggest chocolate may reduce risks of cardiometabolic 
diseases. This study aims to assess the cost-utility of chocolate consumption from 
a US health system perspective. Methods: A cohort life-table analysis was devel-
oped to model life years (LYs) and quality-adjusted life years (QALYs) of chocolate 
consumption versus non-consumption over a lifetime horizon in US adults. Age- 
and sex-specific disease incidence and mortality rates were used to model outcomes 
of cardiometabolic diseases, including coronary heart disease, stroke, and diabetes. 
Relative risks of cardiometabolic disease associated with chocolate consumption 
were obtained from meta-analyses of prospective cohort and cross-sectional stud-
ies. Utility weights, baseline healthcare costs, and attributable disease costs were 
obtained from the literature. Costs of chocolate were estimated based on “high” con-
sumption, consisting of three 150mg chocolate bars per week. Outcomes included 
undiscounted LYs and discounted costs and QALYs. Incremental analyses, strati-
fied by sex, and probabilistic sensitivity analyses (PSAs) were conducted. Results: 
Chocolate consumption, compared to none, increased undiscounted LYs by 0.74 
and 0.99 years and discounted QALYs by 0.54 and 0.45 years for males and females, 
respectively. Cardiometabolic disease costs were reduced by $7,763 and $6,318 and 
total healthcare costs were reduced by $5,660 and $2,717 for males and females, 
respectively. The incremental cost per QALY for chocolate consumption was $1,482 
for males and $8,931 for females. In the PSA chocolate consumption had a 97.8% 
and 89.9% probability of being cost-effective for males and females, respectively, at 
a $50,000/QALY threshold. ConClusions: Chocolate consumption may be a cost-
effective means to reduce the risk of cardiometabolic disease. Given the limitations 
of observational study data, further research is warranted to confirm these findings.
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objeCtives: To conduct an economic evaluation comparing ranolazine plus 
standard-of-care (SoC) relative to SoC alone, in patients with chronic stable angina 
who did not respond adequately to first line therapy, in Greece. Methods: A deci-
sion tree model was locally adapted in the Greek setting to evaluate the cost-utility 
of comparators during a 6-month period. The analysis was conducted from a payer 
(sickness fund) perspective. The clinical inputs were extracted from the published 
literature. The cost inputs considered reflect drug acquisition, hospitalizations, 
vascular interventions and monitoring of patients. Resource utilization data were 
obtained from 3 local experts. All costs refer to the year 2014. Cost-effectiveness 
was assessed by means of the incremental cost per quality adjusted life year 
(QALY) saved with the ranolazine as add-on therapy, relative to SoC alone (ICER). 
Probabilistic sensitivity analysis (PSA) was performed. Results: Ranolazine as 
add-on therapy was more costly compared to SoC alone, as the 6-month total cost 
per patient was € 1,170 and € 984, respectively. Patients received ranolazine plus 
